Transcriptional readthrough progresses from incidental byproduct to therapeutic opportunity
Several anti-cancer drugs delay transcription termination, triggering transcriptional readthrough. Readthrough has long been considered an incidental transcriptional byproduct, however a recent study reveals that it can be functional and might even offer a therapeutic opportunity.
Authors
- Agata Stępień (ORCID: https://orcid.org/0000-0001-9733-7651)
- Kinga Kamieniarz-Gdula (ORCID: https://orcid.org/0000-0003-3789-5381)
- Martyna Plens-Gałąska (ORCID: https://orcid.org/0009-0004-0129-4511)
Institutions
- Adam Mickiewicz University in Poznań (PL)
Publication Details
- Journal
- Nature Structural & Molecular Biology
- Published
- 2026-06-30
- DOI
- https://doi.org/10.1038/s41594-026-01833-4
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00